Zydus Lifesciences secures final USFDA clearance for Cevimeline Hydrochloride Capsules
News by Aliceblue News Desk
13 Mar 2026
Introduction
Leading pharmaceutical company receives USFDA approval for Cevimeline Hydrochloride Capsules 30 mg for treating dry mouth, with production at Ahmedabad SEZ-II facility and significant annual sales.
Also Read: Wanbury Ltd strengthens Brazil dominance with Sertraline Form II approval, here’s what it means
Share price movement of Zydus Lifesciences
On March 13, 2026, Zydus Lifesciences Ltd opened at ₹910.70, down 0.64% from its previous close of ₹916.55. The stock reached a high of ₹922.55 (0.66%) and a low of ₹902.80 (-1.49%). By 12:05 PM, it traded at ₹906.25, a 1.12% decrease, with a market cap of ₹91,189.96 crore.
Zydus Receives USFDA Approval
Zydus Lifesciences Limited has received final approval from the USFDA for Cevimeline Hydrochloride Capsules 30 mg, indicated for treating dry mouth associated with Sjögren’s syndrome.
Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion. The capsules will be manufactured at Zydus’ SEZ-II facility in Ahmedabad, India.
The product had annual sales of USD 26.9 million (IQVIA MAT Jan-26). Zydus now holds 436 approvals and has filed 505 ANDAs since FY 2003-04.
Stock performance of Zydus Lifesciences for period of 1 week, 6 months, and 1 year
Zydus Lifesciences Ltd has delivered a 1-week return of 0.42%, a 6-month return of -12.2%, and a 1-year return of 3.83%.
Also Read: Enviro Infra Engineers rallies 11.5% after securing Aurangabad STP project under AMRUT 2.0
Shareholding pattern of Zydus Lifesciences
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.10% | 7.30% | 7.10% |
| DII | 11.10% | 10.90% | 11.10% |
| Public | 6.90% | 6.80% | 6.70% |
About Zydus Lifesciences
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE), formerly Cadila Healthcare, develops innovative healthcare solutions, focusing on unmet medical needs and promoting healthier communities globally.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Zydus Lifesciences Ltd share price in focus today?
A: Zydus Lifesciences receives USFDA approval for Cevimeline Hydrochloride Capsules 30 mg, produced at Ahmedabad SEZ-II facility.
Q: What is Zydus Lifesciences Ltd’s main business focus?
A: Zydus Lifesciences Ltd develops and markets pharmaceutical products, addressing unmet healthcare needs and promoting healthier communities globally.
Q: What are the 52-week high and low of Zydus Lifesciences Ltd stock?
A: Zydus Lifesciences Ltd stock’s 52-week high is ₹1,059.00 and the 52-week low is ₹797.05.
News Author
Aliceblue News Desk
